AB Science Secures Insurance for Clinical Trial Despite Halt in Europe

AB Science has announced securing a EUR 25 million Clinical Trial Funding Insurance for its Phase III trial in Amyotrophic Lateral Sclerosis (ALS). The insurance policy, arranged by Lloyd’s broker Acrisure Re UK, will cover trial costs up to EUR 39 million if the trial fails, with no deductible, reflecting institutional confidence in the masitinib program.

However, AB Science has implemented a voluntary temporary halt on clinical trials in Europe. This decision comes amid talks with European health authorities over the company’s capacity for conducting such studies. The company is restructuring its strategic priorities, focusing on the ALS trial while scaling back other programs.

The insurance safeguards shareholder capital by potentially reimbursing costs if the trial fails due to several predefined conditions, such as efficacy or safety failures. This financial strategy mitigates risks and enhances capital efficiency for AB Science in its ongoing endeavors.